FLT3 D835Y
|
AML
|
FLT3 D835Y
|
AML
|
midostaurin Sensitive: C2 – Inclusion Criteria
|
midostaurin Sensitive: C2 – Inclusion Criteria
|
FLT3 D835Y
|
AML
|
FLT3 D835Y
|
AML
|
quizartinib Resistant: C3 – Early Trials
|
quizartinib Resistant: C3 – Early Trials
|
FLT3 D835Y
|
AML
|
FLT3 D835Y
|
AML
|
sunitinib Resistant: C3 – Early Trials
|
sunitinib Resistant: C3 – Early Trials
|
FLT3 D835Y
|
AML
|
FLT3 D835Y
|
AML
|
sorafenib Resistant: C3 – Early Trials
|
sorafenib Resistant: C3 – Early Trials
|
FLT3 D835Y
|
AML
|
FLT3 D835Y
|
AML
|
imatinib Sensitive: C4 – Case Studies
|
imatinib Sensitive: C4 – Case Studies
|
FLT3 D835Y
|
AML
|
FLT3 D835Y
|
AML
|
pexidartinib Sensitive: C4 – Case Studies
|
pexidartinib Sensitive: C4 – Case Studies
|
FLT3 D835Y
|
AML
|
FLT3 D835Y
|
AML
|
Max-40279 Sensitive: D – Preclinical
|
Max-40279 Sensitive: D – Preclinical
|
FLT3 D835Y
|
AML
|
FLT3 D835Y
|
AML
|
ponatinib Resistant: D – Preclinical
|
ponatinib Resistant: D – Preclinical
|
FLT3 D835Y
|
AML
|
FLT3 D835Y
|
AML
|
gilteritinib Sensitive: D – Preclinical
|
gilteritinib Sensitive: D – Preclinical
|
FLT3 D835Y
|
AML
|
FLT3 D835Y
|
AML
|
MLN518 Resistant: D – Preclinical
|
MLN518 Resistant: D – Preclinical
|
FLT3 D835Y
|
AML
|
FLT3 D835Y
|
AML
|
SU5614 Sensitive: D – Preclinical
|
SU5614 Sensitive: D – Preclinical
|